Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Read more about Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer Read more about QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma Read more about Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer Read more about Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer Read more about Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer Read more about M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Molecular-Guided Therapy for Childhood Cancer Read more about Molecular-Guided Therapy for Childhood Cancer
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations Read more about Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Read more about A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
Study of Ruxolitinib in Colorectal Cancer Patients Read more about Study of Ruxolitinib in Colorectal Cancer Patients